Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABC.L Regulatory News (ABC)

  • There is currently no data for ABC

Blocklisting Interim Review

14 Aug 2015 13:57

RNS Number : 1309W
ABCAM Plc
14 August 2015
 



For immediate release

14 August 2015

ABCAM PLC

("Abcam" or "the Company")

 

Block Admission Return

Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:

Name of applicant:

Abcam plc

Name of scheme:

1. Abcam EMI Scheme

2. Abcam SAYE Scheme

3. Abcam 2005 Share Option Scheme

4. Abcam Share Incentive Plan

5. Abcam Company Share Option Plan

6. Abcam Long Term Incentive Plan

7. Annual Bonus Plan

Period of return:

From:

6 February 2015

To:

7 August 2015

Balance of unallotted securities under scheme(s) from previous return:

1. 560,915

2. 31,405

3. 2,660,309

4. 281,146

5. 683,238

6. 1,965,749

7. 399,479

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

1. -

2. -

3. -

4. -

5. -

6. -

7. -

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

1. -

2. -

3. 133,504

4. -

5. 53,056

6. -

7. -

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

1. 560,915

2. 31,405

3. 2,526,805

4. 281,146

5. 630,182

6. 1,965,749

7. 399,479

 

Name of contact:

Laura Taylor, Investor Relations

Telephone number of contact:

01223 696000

 

For further information please contact:

Abcam

+ 44 (0) 1223 696 000

Jeff Iliffe, Chief Financial Officer

Laura Taylor, Investor Relations Manager

 

J.P.Morgan Cazenove - Nominated Adviser & Joint Corporate Broker

+ 44 (0) 20 7742 4000

James Mitford / Alex Bruce - Nominated Adviser

Peel Hunt LLP - Joint Corporate Broker

+ 44 (0) 20 7418 8900

Clare Terlouw / Jock Maxwell MacDonald - Corporate Broking

 

FTI Consulting

+44 (0) 20 3727 1000

Ben Atwell / Brett Pollard / Natalie Garland-Collins

 

Notes to Editors

 

About Abcam

Abcam plc is a global leader in the supply of life science research tools, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.

Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company's catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.

Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices enabling local services and multi-language support and sells to over 100 countries. The Company was founded in 1998, and now employs over 750 people. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit www.abcam.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRBDGDILUBBGUS
Date   Source Headline
1st Oct 20204:41 pmRNSTotal Voting Rights
25th Sep 20201:33 pmRNSDirector/PDMR Shareholding
18th Sep 20202:19 pmRNSBlock listing Interim Review
18th Sep 20207:54 amRNSDirector/PDMR Shareholding
14th Sep 20207:00 amRNSFull Year Results 2020
11th Sep 202010:34 amRNSNotice of Results
1st Sep 20207:52 amRNSTotal Voting Rights
4th Aug 202012:57 pmRNSTotal Voting Rights
23rd Jul 20207:00 amRNSChange of Adviser
23rd Jul 20207:00 amRNSFull Year Trading Update
2nd Jul 202010:11 amRNSTotal Voting Rights
16th Jun 202012:00 pmRNSDirectorate Change
1st Jun 20209:29 amRNSTotal Voting Rights
11th May 202011:00 amRNSStatement re Update on 2019 AGM Resolution Vote
1st May 202012:24 pmRNSTotal Voting Rights
22nd Apr 202010:11 amRNSHolding(s) in Company
21st Apr 20207:26 amRNSDirector/PDMR Shareholding
20th Apr 202010:19 amRNSHolding(s) in Company
20th Apr 20207:00 amRNSCOVID-19 Update
14th Apr 202010:07 amRNSHolding(s) in Company
9th Apr 20205:33 pmRNSIssue of Shares
2nd Apr 20209:50 amRNSTotal Voting Rights
27th Mar 20203:37 pmRNSHolding(s) in Company
9th Mar 20207:00 amRNSInterim results for 6 months ended 31 Dec 2019
4th Mar 20207:00 amRNSAcquisition of Marker Gene Technologies
2nd Mar 20203:43 pmRNSTotal Voting Rights
2nd Mar 20208:00 amRNSBlock listing Interim Review
4th Feb 202010:49 amRNSTotal Voting Rights
30th Jan 20207:00 amRNSAbcam expands cell engineering capabilities
28th Jan 20202:31 pmRNSHolding(s) in Company
28th Jan 20202:29 pmRNSDirector/PDMR Shareholding
14th Jan 20207:00 amRNSAppointment of Chief Financial Officer
10th Jan 20207:00 amRNSHalf Year Trading Update
2nd Jan 20209:45 amRNSTotal Voting Rights
2nd Jan 20207:00 amRNSTransaction complete between Abcam and Expedeon
19th Dec 201910:05 amRNSHolding(s) in Company
4th Dec 20193:37 pmRNSHolding(s) in Company
2nd Dec 20193:25 pmRNSDirector/PDMR Shareholding
2nd Dec 20199:30 amRNSTotal Voting Rights
21st Nov 201911:42 amRNSHolding(s) in Company
14th Nov 20197:00 amRNSAbcam Capital Markets Event
13th Nov 20194:45 pmRNSResult of AGM
11th Nov 20197:00 amRNSAbcam to acquire proteomics & immunology business
6th Nov 20199:06 amRNSDirector/PDMR Shareholding
1st Nov 201910:55 amRNSTotal Voting Rights
2nd Oct 20194:28 pmRNSHolding(s) in Company
2nd Oct 20191:49 pmRNSDirector/PDMR Shareholding
1st Oct 20192:22 pmRNSTotal Voting Rights
30th Sep 20191:35 pmRNSAnnual Financial Report
26th Sep 20192:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.